गुड इवनिंग एवरीवन। अ फ्यू मंथ्स बैक इन अ स्टूडेंट लेड कॉन्फ्रेंस इन यंग गर्लफ ऑफ ग्रेट सेन पुट अप एंड शेयरर्ड अबाउट क्रिएटिंग अ पीस गार्डन ऑन कैंपस। अ स्पेस फॉर रिफ्लेक्शन क्वाइट एंड कनेक्शन विद नेचर आल्सो शेयरर्ड दैट वी डोंट नीड मोर क्लासरूम्स रादर वी नीड मोर स्पेसेस टू थिंक एंड दैट अकॉर्डिंग टू मी इज विज़डम व्हिच कैन नॉट बी टॉट थ्रू टेक्स्ट बुक बट नर्चर इन द राइट एनवायरमेंट टुडे वी लिव इन द टाइम्स दैट आर ट्रांसफॉर्मिंग एव्री मिनट बीट आर्टिफिशियल इंटेलिजेंस बीट ग्लोबल कॉन्फ्लिक्ट्स एंड बी इट रिवोल्यूशन ऑफ ड ...

Core Insights - RIBER reaffirms its strategic roadmap during the Annual General Meeting, emphasizing a culture of excellence, continuous innovation, and strong customer focus to position itself at the forefront of the semiconductor industry's transformations, particularly in silicon-based integrated photonics [1][4]. Group 1: Strategic Developments - RIBER introduced ROSIE (Riber Oxide Silicon Epitaxy), an advanced platform for oxide growth on 300 mm wafers, which is fully compatible with SEMI standards, marking a significant technological breakthrough [2]. - The industrialization phase of ROSIE has commenced following a strategic partnership with the Novo Nordisk Foundation Quantum Computing Programme, which includes the qualification of the ROSIE process and the sale of the first unit scheduled for the second half of 2025 [2][3]. Group 2: Financial and Operational Highlights - The Annual General Meeting approved the statutory and consolidated financial statements for the 2024 financial year, along with a cash payout of €0.08 per share, with the ex-dividend date set for June 23, 2025 [6]. - RIBER's strategic positioning is strengthened by solid commercial momentum for its MBE equipment and the industrial rollout of ROSIE, enhancing growth and diversification potential in the semiconductor sector [4]. Group 3: Market Focus - RIBER targets several fast-growing markets, including ultra-fast optical communications, optical computing, and photonic quantum technologies, reflecting its commitment to innovation in the semiconductor industry [7]. - The company plays a crucial role in the development of advanced semiconductors used in various applications, from information technologies to 5G telecommunications networks and quantum computing [8].

Core Insights - VEON Ltd. announces that Kyivstar has received regulatory approval for testing Starlink Direct-to-Cell (D2C) services in Ukraine, marking a significant step towards enhancing connectivity in the region [1][4] - Successful integration of Kyivstar's SIM cards with Starlink's satellite network has been confirmed, indicating compatibility and paving the way for the launch of D2C services [2] - The planned launch of D2C services, which will support SMS and over-the-top (OTT) messaging, is set for Q4 2025, aimed at improving connectivity in areas affected by infrastructure damage and during emergencies [3] Company Overview - VEON is a digital operator serving nearly 160 million customers across six countries, focusing on technology-driven services that promote economic growth [5] - Kyivstar, as Ukraine's largest digital operator, serves over 23 million mobile subscribers and has committed to investing USD 1 billion in telecom technologies from 2023 to 2027 [6] - Kyivstar has allocated over UAH 2 billion in the past two years to support wartime challenges, including assistance to the Armed Forces and social projects [6]

Salesforce NYSE: CRM raised its prices, and its share price will soon follow for three reasons that begin and end with its pricing decision. The decision may appear to be bad news, impairing the company’s appeal to its consumers, but it aligns with technology industry trends and will ultimately accelerate its growth. Salesforce TodayCRMSalesforce$260.77 -1.57 (-0.60%) 52-Week Range$229.23▼$369.00Dividend Yield0.64%P/E Ratio40.77Price Target$346.34Add to WatchlistThe increase, worth an average of 6% across ...

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time. Benzinga All-Access Show Date: Wednesday, June 18, 2025 Time: 10:50 a.m. Eastern Ti ...

Core Insights - SailPoint Inc. focuses on identity security, providing identity governance and administration services to manage user identities and access rights across various sectors [1] - The company has seen significant stock performance since its recent IPO, with shares increasing by over 6% since February 2025 and a notable 28% rise in the last month [2][3] - Analysts view SailPoint as a potential leader in the cybersecurity industry, with 10 analysts rating the stock as a Buy and several firms raising their price targets [3] Financial Performance - SailPoint reported a 23% year-over-year increase in revenue, reaching $230 million for the latest quarter [4] - The company achieved a 30% year-over-year growth in Annual Recurring Revenue (ARR), totaling $925 million, with SaaS ARR surging by 39% [5] - Full-year guidance has been raised, with expectations for ARR growth of up to 26% year-over-year in fiscal 2026 [6] Competitive Positioning - SailPoint differentiates itself in the crowded cybersecurity market through its AI-driven enterprise security systems, which operate independently of human input [7] - Recent partnerships, including an expanded collaboration with Deloitte and new SaaS partnerships in South America and the Middle East, highlight the strength of SailPoint's approach [8] Stock Forecast - The 12-month stock price forecast for SailPoint is $26.50, indicating a potential upside of 15.47% from the current price of $22.95 [9] - The company is approaching the Rule of 40 threshold, aiming for a combined revenue growth rate and profit margin in the high-30% range [10]

LAS VEGAS, June 18, 2025 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that its next-generation Merchant Point-of-Sale (QR POS) platform is now open for merchant registration. This milestone paves the way for a seamless rollout of a robust, secure, and feature-rich POS system designed to empower retailers, restaurants, and service providers with real-time payment processing and business insights. The primary payment tool for the Company’s soon to be rel ...

关于近期经营情况的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688692 证券简称：达梦数据 公告编号：2025-031 武汉达梦数据库股份有限公司 武汉达梦数据库股份有限公司（以下简称"公司"）专注于数据库领域相 关产品的研发和销售，主要提供各类数据库软件及集群软件、云计算与大数据 产品等一系列数据库产品及相关技术服务。公司自上市以来，始终聚焦主责主 业、提升核心竞争力，着眼促进公司高质量发展，树立狠抓技术、产品、市场、 人才的鲜明导向，统筹推进各项工作，基本实现了稳健经营、快速发展。 截至目前，公司经营情况良好，据公司财务部门初步测算，公司 2025 年 1-6 月预计实现营业收入 4.95-5.13 亿元，较去年同期增长 40.63%-45.74%。 二、 相关风险提示 武汉达梦数据库股份有限公司董事会 2025年6月18日 一、 近期经营情况 本公告所载近期财务数据为初步核算数据，未经会计师事务所审计，仅作 为阶段性财务数据供投资者参考，不能以此推算公司全年业绩情况，具体数据 请以公 ...

Asia Insights Economics - Asia ex-Japan China: Credit growth remained steady in May despite disappointing loan growth New aggregate financing (AF) came in slightly below the market expectations, with outstanding AF growth unchanged. The downside surprise to consensus was aqain primarily driven by much weaker-than-expected new RMB loans, with the growth rate of outstanding loans dropping again and reaching another historical low. Again, we think the sharp slowdown in loan growth was mostly driven by the ongo ...

Core Insights - Ascletis Pharma Inc. has initiated a Phase I clinical trial for ASC50, an oral small molecule inhibitor targeting interleukin-17 (IL-17), aimed at treating psoriasis [2][3] - The trial is randomized, double-blind, and placebo-controlled, involving both healthy participants and patients with mild-to-moderate plaque psoriasis [3] - Preclinical data suggests that ASC50 has higher oral exposure, a longer half-life, and strong efficacy, positioning it as a potential best-in-class treatment for psoriasis [1] Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing innovative therapeutics for metabolic diseases [4] - The company utilizes its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP) to develop drug candidates in-house [4] - Ascletis is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [4]